Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal ...

The size and scope of the FDA that began Tuesday won’t be the same as the day nears a brutal conclusion for agency staffers ...

Eli Lilly has sued two large compounding pharmacies, alleging they deceive patients and put them at risk with compounded ...

HHS Secretary Robert F. Kennedy Jr. has made clear that he would like to ban direct-to-consumer drug advertisements on ...

The European Medicines Agency is looking to simplify the way it approves biosimilars by removing the need for “extensive” ...

Zus Health, led by former athenahealth CEO Jonathan Bush, aims to create unified health records. Company has 60+ customers ...

Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major depressive disorder.

Compass Therapeutics said Tuesday that adding its bispecific antibody to chemotherapy significantly improved response rates compared to chemotherapy alone in a Phase 2/3 study.

GUBamy, AbbVie-licensed amylin drug from Gubra, shows 7.8% weight loss in Phase 1 trial, vs 2% weight gain with placebo after ...

Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into ...

Prazer Therapeutics raises $20M Series B with JJDC's first South Korean investment; Carisma cuts to 6 staff; Cerevance's Parkinson's trial fails; FDA updates for Oncopeptides, Bavarian Nordic ...

Talkspace is using AI to make mini podcast episodes from patients’ therapy sessions. The “Talkcast” episodes are meant to be ...